TransMedics Group, Inc. (NASDAQ:TMDX) Stake Lessened by Bank of New York Mellon Corp

Bank of New York Mellon Corp cut its stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 62.1% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 209,677 shares of the company's stock after selling 343,585 shares during the quarter. Bank of New York Mellon Corp owned about 0.62% of TransMedics Group worth $14,107,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Vanguard Group Inc. grew its stake in shares of TransMedics Group by 1.1% during the 4th quarter. Vanguard Group Inc. now owns 3,635,919 shares of the company's stock worth $226,700,000 after purchasing an additional 40,860 shares during the period. FIL Ltd grew its stake in TransMedics Group by 28.0% in the 4th quarter. FIL Ltd now owns 1,000,358 shares of the company's stock valued at $62,372,000 after acquiring an additional 218,961 shares during the last quarter. Braidwell LP acquired a new stake in TransMedics Group in the 4th quarter valued at about $57,493,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in TransMedics Group by 16.6% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 903,086 shares of the company's stock valued at $56,307,000 after acquiring an additional 128,474 shares during the last quarter. Finally, Mackenzie Financial Corp grew its stake in TransMedics Group by 73.0% in the 4th quarter. Mackenzie Financial Corp now owns 828,147 shares of the company's stock valued at $51,635,000 after acquiring an additional 349,403 shares during the last quarter. 99.67% of the stock is owned by institutional investors and hedge funds.

TransMedics Group Trading Up 4.1%

Shares of TransMedics Group stock traded up $4.37 during mid-day trading on Wednesday, hitting $109.97. 1,121,046 shares of the stock were exchanged, compared to its average volume of 1,394,381. TransMedics Group, Inc. has a twelve month low of $55.00 and a twelve month high of $177.37. The stock has a market capitalization of $3.72 billion, a price-to-earnings ratio of 80.86 and a beta of 2.06. The company has a 50-day simple moving average of $126.25 and a 200 day simple moving average of $93.09. The company has a current ratio of 9.10, a quick ratio of 8.32 and a debt-to-equity ratio of 1.92.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.29 by $0.41. The business had revenue of $143.54 million for the quarter, compared to analyst estimates of $123.39 million. TransMedics Group had a net margin of 10.03% and a return on equity of 21.88%. The company's revenue was up 48.2% on a year-over-year basis. During the same period in the prior year, the firm posted $0.35 EPS. Research analysts forecast that TransMedics Group, Inc. will post 1 EPS for the current year.

Analysts Set New Price Targets

TMDX has been the topic of a number of research reports. Canaccord Genuity Group increased their price objective on shares of TransMedics Group from $129.00 to $142.00 and gave the company a "buy" rating in a research note on Tuesday, July 15th. Piper Sandler reissued an "overweight" rating and issued a $145.00 price objective (up from $125.00) on shares of TransMedics Group in a research note on Wednesday, June 4th. Oppenheimer increased their price objective on shares of TransMedics Group from $130.00 to $150.00 and gave the company an "outperform" rating in a research note on Tuesday, June 17th. Finally, Needham & Company LLC reissued a "hold" rating on shares of TransMedics Group in a research note on Tuesday, June 17th. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, TransMedics Group presently has a consensus rating of "Moderate Buy" and a consensus target price of $129.88.

Insider Buying and Selling at TransMedics Group

In other TransMedics Group news, Director David Weill sold 732 shares of TransMedics Group stock in a transaction that occurred on Friday, May 23rd. The shares were sold at an average price of $123.88, for a total transaction of $90,680.16. Following the transaction, the director directly owned 12,134 shares of the company's stock, valued at $1,503,159.92. The trade was a 5.69% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Edward M. Basile sold 6,000 shares of TransMedics Group stock in a transaction that occurred on Friday, May 9th. The shares were sold at an average price of $115.63, for a total transaction of $693,780.00. Following the transaction, the director directly owned 732 shares in the company, valued at approximately $84,641.16. This trade represents a 89.13% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 12,418 shares of company stock valued at $1,512,613 over the last ninety days. Corporate insiders own 7.00% of the company's stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.